Breast Cancer Clinical Trials

**SUSPENDED** ALLIANCE A011104  Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (Feig)

UCI 15-83  Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting (Tromberg)

UCI 10-39  Predicting Pathological Response within the First Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured with Diffuse Optical Spectroscopic Imaging (DOSI) (Tromberg)

UCI 11-15  Correlation of Clinical and MRI Findings with Prognosis of Breast Cancer Patients (Su)

UCI 11-21  Analysis of Imaging Features of Breast Diseases and Breast Density Evaluated on Mammogram, Ultrasound & MRI Collected in a Database (Su)

UCI 14-86  Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System (Su)

UCI 16-23  Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] (Anton-Culver)

---

**SUSPENDED**

ALLIANCE A011104  Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (Feig)

UCI 15-83  Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting (Tromberg)

UCI 10-39  Predicting Pathological Response within the First Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured with Diffuse Optical Spectroscopic Imaging (DOSI) (Tromberg)

UCI 11-15  Correlation of Clinical and MRI Findings with Prognosis of Breast Cancer Patients (Su)

UCI 11-21  Analysis of Imaging Features of Breast Diseases and Breast Density Evaluated on Mammogram, Ultrasound & MRI Collected in a Database (Su)

UCI 14-86  Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System (Su)

UCI 16-23  Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] (Anton-Culver)

---

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**opening soon** 0218
Breast Cancer Therapeutic Clinical Trials

**BREAST CANCER**

**Neo- Adjuvant**

- **UCI 14-67** A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (Mehta)

**Stage I-III**

**Adjuvant**

- **NSABP B51** A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (Darouei)

**Hormone+ High Risk**

**ALLIANCE A011502** A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (Mehta)

**UCI 17-62** A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer (Parajuli)

**HER2- High Risk**

- **SWOG S1418** Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy (Mehta)

- **SWOG S1207** Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer (Mehta)

**Adjuvant**

- **ALLIANCE A011502** A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (Mehta)

**Neo- Adjuvant**

- **UCI 14-67** A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (Mehta)

For more details contact 1-877-UC-STUDY or ucsstudy@uci.edu

**opening soon**

0218
**UCI 17-90** A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy (**Ou**)

**UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (**Ou**)

UCI 16-74 A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (**Carrillo**)

**SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (**Bota**)

**ECOG EAY131** Molecular Analysis for Therapy Choice (MATCH) (**Bota**)

**NRG BR002** A Phase II/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (**DarouI**)

**UCI 17-79** Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (**Parajuli**)

For more details contact 1-877-UC-STUDY or ucsudy@uci.edu